Next Article in Journal
Homeobox Genes and Hepatocellular Carcinoma
Previous Article in Journal
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer

Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
Translational Research Institute, Brisbane, QLD 4102, Australia
Royal North Shore Hospital, Sydney, NSW 2065, Australia
Author to whom correspondence should be addressed.
Cancers 2019, 11(5), 620;
Received: 16 April 2019 / Revised: 30 April 2019 / Accepted: 30 April 2019 / Published: 3 May 2019
PDF [506 KB, uploaded 3 May 2019]
  |     |  


Identifying and targeting specific oncogenic drivers has become standard of care in the routine management of patients with lung cancer. Research is ongoing to expand the number of drug targets that can offer clinically meaningful outcomes. Rearranged during transfection (RET) fusions are the latest oncogenic driver alterations that show potential as a drug target. RET fusions occur in 1–2% of non-small cell lung cancer (NSCLC) cases. They are more commonly associated with younger age, female gender, non-smokers and Asian ethnicity. The RET kinase is abnormally activated through fusion with a partner protein such as KIF5B, CCDC6 or NCOA4. This leads to downstream intracellular signalling and enhancement of gene transcription and cell proliferation. The effectiveness of multi-kinase inhibitors in RET positive NSCLC has been explored in early phase and retrospective studies. From these studies, the most effective agents identified include cabozantanib and vandetanib. Overall response rates (ORR) vary from 18–47% across studies. In general, these agents have a manageable toxicity profile, although there are a number of off-target toxicities. Similar to the increased activity in ALK rearranged disease, pemetrexed has demonstrated superior response rates in this patient group and should be considered. Selective RET inhibitors, including LOXO-292 and BLU-667, are progressing in clinical trials. LOXO-292 has demonstrated an impressive ORR of 77% in RET positive solid tumours. It is anticipated this agent will be an effective targeted therapeutic option for patients with RET positive lung cancer. View Full-Text
Keywords: non-small cell lung cancer; rearranged during transfection; RET fusions non-small cell lung cancer; rearranged during transfection; RET fusions

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

O’Leary, C.; Xu, W.; Pavlakis, N.; Richard, D.; O’Byrne, K. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer. Cancers 2019, 11, 620.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top